IC
RCUS icon

Ikarian Capital’s Arcus Biosciences RCUS Stock Holding History

Ikarian Capital’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-283,100
Closed -$5.85M – 131
2022
Q4 		$5.85M Buy
+283,100
New +$7.79M 1.41% 23
2022
Q3 		– Sell
-50,000
Closed -$1.27M – 152
2022
Q2 		$1.27M Buy
+50,000
New +$1.22M 0.23% 72
2022
Q1 		– Sell
-124,600
Closed -$5.04M – 208
2021
Q4 		$5.04M Buy
+124,600
New +$4.83M 0.75% 35
2021
Q3 		– Sell
-245,500
Closed -$6.74M – 247
2021
Q2 		$6.74M Hold
245,500
– – 0.55% 51
2021
Q1 		$6.89M Buy
245,500
+225,000
+1,098% +$7.83M 0.23% 95
2020
Q4 		$532K Buy
+20,500
New +$496K 0.02% 190

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital's RCUS Position: Q3 2025 in Review

Ikarian Capital sold out of Arcus Biosciences (RCUS) in Q3 2025, closing a stake of 163,363 shares — an estimated $1.33M sold.

Ikarian Capital first reported a position in RCUS in Q4 2022 and held it in 9 quarters. The position peaked at $11.4M in Q3 2024. 190 funds tracked by Wall St. Rank hold RCUS as of Q3 2025.

  • Ikarian Capital reported no remaining Arcus Biosciences position as of Q3 2025 after selling out during the quarter.
  • Ikarian Capital sold 163,363 Arcus Biosciences shares in Q3 2025, an estimated $1.33M.
  • Ikarian Capital first reported a position in Arcus Biosciences in Q4 2022 and held it in 9 quarters.
  • Ikarian Capital's Arcus Biosciences position peaked at $11.4M in Q3 2024.
  • 190 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2025.

Based on Ikarian Capital's 13F filing for Q3 2025, filed 14 Nov 2025.